Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Pulmonary Arterial Hypertension associated with Protein Kinase Inhibitors: A pharmacovigilance-pharmacodynamic study.

Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, Revol B, Despas F, Montani D, Cracowski JL.

Eur Respir J. 2019 Mar 7. pii: 1802472. doi: 10.1183/13993003.02472-2018. [Epub ahead of print]

PMID:
30846469
2.

Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study.

Vadasz Z, Balbir Gurman A, Meroni P, Farge D, Levi Y, Ingegnoli F, Braun-Moscovici Y, Rosner I, Slobodin G, Rozenbaum M, Jiries N, Kaly L, Boulman N, Zilber K, Ginsberg S, Awisat A, Goldberg Y, Lurie M, Ghigna MR, Guignabert C, Humbert M, Rimar D.

Rheumatology (Oxford). 2019 Feb 15. pii: kez035. doi: 10.1093/rheumatology/kez035. [Epub ahead of print]

PMID:
30770717
3.

PPARγ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis.

Li CG, Mahon C, Sweeney NM, Verschueren E, Kantamani V, Li D, Hennigs JK, Marciano DP, Diebold I, Abu-Halawa O, Elliott M, Sa S, Guo F, Wang L, Cao A, Guignabert C, Sollier J, Nickel NP, Kaschwich M, Cimprich KA, Rabinovitch M.

Cell Rep. 2019 Jan 29;26(5):1333-1343.e7. doi: 10.1016/j.celrep.2019.01.013.

4.

Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension.

Tu L, Desroches-Castan A, Mallet C, Guyon L, Cumont A, Phan C, Robert F, Thuillet R, Bordenave J, Sekine A, Huertas A, Ritvos O, Savale L, Feige JJ, Humbert M, Bailly S, Guignabert C.

Circ Res. 2019 Mar 15;124(6):846-855. doi: 10.1161/CIRCRESAHA.118.313356.

PMID:
30636542
5.

Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction.

Karmouty-Quintana H, Guignabert C, Kwapiszewska G, Ormiston ML.

Front Physiol. 2018 Dec 10;9:1777. doi: 10.3389/fphys.2018.01777. eCollection 2018. No abstract available.

6.

Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis.

Günther S, Bordenave J, Hua-Huy T, Nicco C, Cumont A, Thuillet R, Tu L, Quatremarre T, Guilbert T, Jalce G, Batteux F, Humbert M, Savale L, Guignabert C, Dinh-Xuan AT.

Int J Mol Sci. 2018 Dec 18;19(12). pii: E4105. doi: 10.3390/ijms19124105.

7.

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.

Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801887. doi: 10.1183/13993003.01887-2018. Print 2019 Jan.

8.

Functional interaction between PDGFβ and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension.

Quatredeniers M, Nakhleh MK, Dumas SJ, Courboulin A, Vinhas MC, Antigny F, Phan C, Guignabert C, Bendifallah I, Vocelle M, Fadel E, Dorfmüller P, Humbert M, Cohen-Kaminsky S.

Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L445-L455. doi: 10.1152/ajplung.00537.2017. Epub 2018 Dec 13.

PMID:
30543306
9.

Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension.

Poble PB, Phan C, Quatremare T, Bordenave J, Thuillet R, Cumont A, Huertas A, Tu L, Dorfmüller P, Humbert M, Ghigna MR, Savale L, Guignabert C.

FASEB J. 2019 Mar;33(3):3670-3679. doi: 10.1096/fj.201801659R. Epub 2018 Nov 27.

PMID:
30481487
10.

[IL6R is the key therapeutical target in pulmonary arterial hypertension].

Tu L, Phan C, Humbert M, Guignabert C.

Med Sci (Paris). 2018 Oct;34(10):765-768. doi: 10.1051/medsci/2018201. Epub 2018 Nov 19. French. No abstract available.

PMID:
30451672
11.

Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets.

Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F.

Drug Discov Today. 2019 Feb;24(2):428-439. doi: 10.1016/j.drudis.2018.11.003. Epub 2018 Nov 13. Review.

PMID:
30439447
12.

Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.

Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, Dewey FE, Overton JD, Reid JG, Shuldiner AR, Baras A, Sampson KJ, Bleda M, Hadinnapola C, Haimel M, Bogaard HJ, Church C, Coghlan G, Corris PA, Eyries M, Gibbs JSR, Girerd B, Houweling AC, Humbert M, Guignabert C, Kiely DG, Lawrie A, MacKenzie Ross RV, Martin JM, Montani D, Peacock AJ, Pepke-Zaba J, Soubrier F, Suntharalingam J, Toshner M, Treacy CM, Trembath RC, Vonk Noordegraaf A, Wharton J, Wilkins MR, Wort SJ, Yates K, Gräf S, Morrell NW, Krishnan U, Rosenzweig EB, Shen Y, Nichols CG, Kass RS, Chung WK.

Circ Genom Precis Med. 2018 Oct;11(10):e002087. doi: 10.1161/CIRCGEN.118.002087.

PMID:
30354297
13.

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.

Boleto G, Guignabert C, Pezet S, Cauvet A, Sadoine J, Tu L, Nicco C, Gobeaux C, Batteux F, Allanore Y, Avouac J.

Arthritis Res Ther. 2018 Aug 29;20(1):197. doi: 10.1186/s13075-018-1694-9.

14.

Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension.

Chaumais MC, O'Connell C, Savale L, Guignabert C, Perros F, Jaïs X, Sitbon O, Humbert M, Montani D.

Int J Clin Pharm. 2018 Aug;40(4):790-794. doi: 10.1007/s11096-018-0712-y. Epub 2018 Aug 13.

PMID:
30101375
15.

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.

Rol N, de Raaf MA, Sun XQ, Kuiper VP, da Silva Gonçalves Bos D, Happé C, Kurakula K, Dickhoff C, Thuillet R, Tu L, Guignabert C, Schalij I, Lodder K, Pan X, Herrmann FE, van Nieuw Amerongen GP, Koolwijk P, Vonk-Noordegraaf A, de Man FS, Wollin L, Goumans MJ, Szulcek R, Bogaard HJ.

Cardiovasc Res. 2019 Feb 1;115(2):432-439. doi: 10.1093/cvr/cvy186.

PMID:
30032282
16.

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad.

Guignabert C, de Man F, Lombès M.

Eur Respir J. 2018 Jun 21;51(6). pii: 1800848. doi: 10.1183/13993003.00848-2018. Print 2018 Jun. No abstract available.

PMID:
29929959
17.

Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension.

Mertens TCJ, Hanmandlu A, Tu L, Phan C, Collum SD, Chen NY, Weng T, Davies J, Liu C, Eltzschig HK, Jyothula SSK, Rajagopal K, Xia Y, Guha A, Bruckner BA, Blackburn MR, Guignabert C, Karmouty-Quintana H.

Front Physiol. 2018 Jun 1;9:555. doi: 10.3389/fphys.2018.00555. eCollection 2018.

18.

Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, Jevnikar M, Savale L, Jaïs X, Peng M, Simonneau G, Montani D, Humbert M, Sitbon O.

Chest. 2018 Oct;154(4):872-881. doi: 10.1016/j.chest.2018.05.006. Epub 2018 May 22.

PMID:
29800550
19.

Optimising experimental research in respiratory diseases: an ERS statement.

Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzenrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooy JHJ, Richeldi L, Kolb M.

Eur Respir J. 2018 May 17;51(5). pii: 1702133. doi: 10.1183/13993003.02133-2017. Print 2018 May.

PMID:
29773606
20.

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.

Savale L, Guignabert C, Weatherald J, Humbert M.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Review.

21.

Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, Fadel E, Savale L, Huertas A, Humbert M, Guignabert C.

J Clin Invest. 2018 May 1;128(5):1956-1970. doi: 10.1172/JCI96462. Epub 2018 Apr 9.

22.

Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy.

Huertas A, Guignabert C, Barberà JA, Bärtsch P, Bhattacharya J, Bhattacharya S, Bonsignore MR, Dewachter L, Dinh-Xuan AT, Dorfmüller P, Gladwin MT, Humbert M, Kotsimbos T, Vassilakopoulos T, Sanchez O, Savale L, Testa U, Wilkins MR.

Eur Respir J. 2018 Apr 4;51(4). pii: 1700745. doi: 10.1183/13993003.00745-2017. Print 2018 Apr. Review.

PMID:
29545281
23.

Update in Pulmonary Vascular Disease 2016 and 2017.

Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C, Paulin R, Machado RF, Yu PB.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):13-23. doi: 10.1164/rccm.201801-0062UP. No abstract available.

PMID:
29533671
24.

Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension.

Le Hiress M, Akagah B, Bernadat G, Tu L, Thuillet R, Huertas A, Phan C, Fadel E, Simonneau G, Humbert M, Jalce G, Guignabert C.

J Med Chem. 2018 Apr 12;61(7):2725-2736. doi: 10.1021/acs.jmedchem.7b01312. Epub 2018 Mar 19.

PMID:
29526099
25.

Dasatinib increases endothelial permeability leading to pleural effusion.

Phan C, Jutant EM, Tu L, Thuillet R, Seferian A, Montani D, Huertas A, Bezu JV, Breijer F, Vonk Noordegraaf A, Humbert M, Aman J, Guignabert C.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701096. doi: 10.1183/13993003.01096-2017. Print 2018 Jan.

PMID:
29348177
26.

Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

da Silva Gonçalves Bós D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, Dos Remedios C, Guignabert C, Tu L, Dorfmüller P, Humbert M, Wijnker PJM, Kuster DWD, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, de Man FS, Handoko ML.

Circulation. 2018 Feb 27;137(9):910-924. doi: 10.1161/CIRCULATIONAHA.117.027451. Epub 2017 Nov 22.

PMID:
29167228
27.

A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population.

Kimura M, Tamura Y, Guignabert C, Takei M, Kosaki K, Tanabe N, Tatsumi K, Saji T, Satoh T, Kataoka M, Kamitsuji S, Kamatani N, Thuillet R, Tu L, Humbert M, Fukuda K, Sano M.

Oncotarget. 2017 Aug 24;8(43):74917-74926. doi: 10.18632/oncotarget.20459. eCollection 2017 Sep 26.

28.

Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension.

da Silva Gonçalves Bos D, Happé C, Schalij I, Pijacka W, Paton JFR, Guignabert C, Tu L, Thuillet R, Bogaard HJ, van Rossum AC, Vonk-Noordegraaf A, de Man FS, Handoko ML.

JACC Basic Transl Sci. 2017 Feb 1;2(1):22-35. doi: 10.1016/j.jacbts.2016.09.007. eCollection 2017 Feb.

29.

Pathology and Pathobiology of Pulmonary Hypertension.

Guignabert C, Dorfmüller P.

Semin Respir Crit Care Med. 2017 Oct;38(5):571-584. doi: 10.1055/s-0037-1606214. Epub 2017 Oct 15. Review. No abstract available.

PMID:
29032561
30.

Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.

Avouac J, Guignabert C, Hoffmann-Vold AM, Ruiz B, Dorfmuller P, Pezet S, Amar O, Tu L, Van Wassenhove J, Sadoine J, Launay D, Elhai M, Cauvet A, Subramaniam A, Resnick R, Hachulla E, Molberg Ø, Kahan A, Humbert M, Allanore Y.

Arthritis Rheumatol. 2017 Nov;69(11):2209-2221. doi: 10.1002/art.40229. Epub 2017 Oct 17.

31.

Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.

Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, Cauvet A, Tu L, Luccarini JM, Junien JL, Broqua P, Allanore Y.

Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.

PMID:
28801346
32.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

33.

New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways.

Huertas A, Tu L, Guignabert C.

Curr Opin Pulm Med. 2017 Sep;23(5):377-385. doi: 10.1097/MCP.0000000000000404. Review.

PMID:
28582316
34.

Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".

Weatherald J, Humbert M, Guignabert C, Montani D.

Pulm Pharmacol Ther. 2017 Aug;45:11-12. doi: 10.1016/j.pupt.2017.03.017. Epub 2017 Apr 4. No abstract available.

PMID:
28389260
35.

Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations.

Guignabert C, Bailly S, Humbert M.

Expert Opin Ther Targets. 2017 Feb;21(2):181-190. doi: 10.1080/14728222.2017.1275567. Epub 2016 Dec 28. Review.

PMID:
28001443
36.

Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension.

Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.

J Pharmacol Exp Ther. 2017 Feb;360(2):267-279. doi: 10.1124/jpet.116.237933. Epub 2016 Dec 7.

PMID:
27927914
37.

BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.

Ghigna MR, Guignabert C, Montani D, Girerd B, Jaïs X, Savale L, Hervé P, Thomas de Montpréville V, Mercier O, Sitbon O, Soubrier F, Fadel E, Simonneau G, Humbert M, Dorfmüller P.

Eur Respir J. 2016 Dec;48(6):1668-1681. doi: 10.1183/13993003.00464-2016. Epub 2016 Nov 3.

38.

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.

Riou M, Seferian A, Savale L, Chaumais MC, Guignabert C, Canuet M, Magro P, Rea D, Sitbon O, Jaïs X, Humbert M, Montani D.

Eur Respir J. 2016 Nov;48(5):1517-1519. doi: 10.1183/13993003.01410-2016. Epub 2016 Oct 6. No abstract available.

39.

[Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications].

Tu L, Ghigna MR, Phan C, Bordenave J, Le Hiress M, Thuillet R, Ricard N, Huertas A, Humbert M, Guignabert C.

Biol Aujourdhui. 2016;210(2):65-78. doi: 10.1051/jbio/2016010. Epub 2016 Sep 30. Review. French.

PMID:
27687598
40.

Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):583-595. doi: 10.1164/rccm.201607-1515PP. Review. No abstract available.

41.

Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.

Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Manéglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M.

J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.

42.

Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.

de Raaf MA, Herrmann FE, Schalij I, de Man FS, Vonk-Noordegraaf A, Guignabert C, Wollin L, Bogaard HJ.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H604-12. doi: 10.1152/ajpheart.00656.2015. Epub 2016 Jun 24.

43.

Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension.

Huertas A, Phan C, Bordenave J, Tu L, Thuillet R, Le Hiress M, Avouac J, Tamura Y, Allanore Y, Jovan R, Sitbon O, Guignabert C, Humbert M.

Chest. 2016 Jun;149(6):1482-93. doi: 10.1016/j.chest.2016.01.004. Epub 2016 Jan 21.

PMID:
26836928
44.

Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage.

Szulcek R, Happé CM, Rol N, Fontijn RD, Dickhoff C, Hartemink KJ, Grünberg K, Tu L, Timens W, Nossent GD, Paul MA, Leyen TA, Horrevoets AJ, de Man FS, Guignabert C, Yu PB, Vonk-Noordegraaf A, van Nieuw Amerongen GP, Bogaard HJ.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1410-20. doi: 10.1164/rccm.201506-1231OC.

PMID:
26760925
45.

Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension.

Izikki M, Hoang E, Draskovic I, Mercier O, Lecerf F, Lamrani L, Liu WY, Guignabert C, Fadel E, Dorfmuller P, Humbert M, Londoño-Vallejo A, Eddahibi S.

J Am Coll Cardiol. 2015 Oct 27;66(17):1942-3. doi: 10.1016/j.jacc.2015.08.869. No abstract available.

46.

Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study.

Perrin S, Montani D, O'Connell C, Günther S, Girerd B, Savale L, Guignabert C, Sitbon O, Simonneau G, Humbert M, Chaumais MC.

Eur Respir J. 2015 Oct;46(4):1211-4. doi: 10.1183/13993003.00051-2015. Epub 2015 Jul 23. No abstract available.

47.

Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex.

Le Hiress M, Tu L, Ricard N, Phan C, Thuillet R, Fadel E, Dorfmüller P, Montani D, de Man F, Humbert M, Huertas A, Guignabert C.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):983-97. doi: 10.1164/rccm.201402-0322OC.

PMID:
26203495
48.

Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.

de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.

Reprod Toxicol. 2015 Aug 15;56:45-51. doi: 10.1016/j.reprotox.2015.06.048. Epub 2015 Jun 22. Review.

PMID:
26111581
49.

Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension.

Freund-Michel V, Cardoso Dos Santos M, Guignabert C, Montani D, Phan C, Coste F, Tu L, Dubois M, Girerd B, Courtois A, Humbert M, Savineau JP, Marthan R, Muller B.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):342-55. doi: 10.1164/rccm.201410-1851OC.

PMID:
26039706
50.

Leptin signalling system as a target for pulmonary arterial hypertension therapy.

Huertas A, Tu L, Thuillet R, Le Hiress M, Phan C, Ricard N, Nadaud S, Fadel E, Humbert M, Guignabert C.

Eur Respir J. 2015 Apr;45(4):1066-80. doi: 10.1183/09031936.00193014. Epub 2015 Mar 5.

Supplemental Content

Loading ...
Support Center